Metropolis HealthcareNSE:METROPOLIS +1.41%95 ROA % is 9.52% as of Mar. 2026, which is 48% below its 10-year median of 18.21. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 86.38% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Metropolis Healthcare's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹2,036 Mil.
Metropolis Healthcare's average Total Assets over the quarter that ended in Mar. 2026 was ₹21,381 Mil. Therefore, Metropolis Healthcare's annualized ROA % for the quarter that ended in Mar. 2026 was 9.52%.
The historical rank and industry rank for Metropolis Healthcare's ROA % or its related term are showing as below:
NSE:METROPOLIS'
s ROA % Range Over the Past 10 Years
Min: 8.36 Med: 18.21 Max: 22.32
Current: 9.5
During the past 11 years, Metropolis Healthcare's highest ROA % was 22.32%. The lowest was 8.36%. And the median was 18.21%.
NSE:METROPOLIS's ROA % is ranked better than 86.38% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.87
vs NSE:METROPOLIS: 9.50
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: ROA % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's ROA % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Metropolis Healthcare (NSE:METROPOLIS) has a ROA % of 9.52% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Metropolis Healthcare and its competitors. This is 48% below median its historical median of 18.21. Over the past decade, Metropolis Healthcare's ROA % has ranged from 8.36 to 22.32. According to the industry distribution chart, Metropolis Healthcare ranks #29 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 13.6%.
Is Metropolis Healthcare's ROA % too high?
Metropolis Healthcare's current ROA % of 9.52% is 48% below median its 10-year median of 18.21. Over the past 10 years, this metric has ranged from a low of 8.36 to a high of 22.32. Based on the distribution chart, Metropolis Healthcare ranks #29 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #29 out of 213 companies for ROA %. This places Metropolis Healthcare in the top 14% of its industry — outperforming the majority of peers. Historically, Metropolis Healthcare's own ROA % has ranged from 8.36 to 22.32 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current ROA % is 9.52%, which is 48% below median its own 10-year median of 18.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current ROA % is 9.52%, which is 48% below median its 10-year median of 18.21. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current ROA % is 9.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
ROA %: 9.52% (48% below median its 10-year median of 18.21)
GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score
Get the complete analysis for NSE:METROPOLIS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
